

iDose® TR (travoprost intracameral implant)

When requesting iDose® TR (travoprost intracameral implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Coverage Guidelines

Reduction of intraocular pressure (IOP) with open-angle glaucoma (OAG) or ocular hypertension (OHT)

The individual must meet all of the following criteria for authorization:

- Is 18 years of age or older;
- Has experienced inadequate efficacy or severe adverse event(s) to at least two ophthalmic prostaglandins (as monotherapy or concomitant therapy) for the treatment of open-angle glaucoma or ocular hypertension (e.g., bimatoprost ophthalmic solution, latanoprost ophthalmic solution, travoprost ophthalmic solution, latanoprostene bunod ophthalmic solution, tafluprost ophthalmic solution, omidenepag isopropyl ophthalmic solution);
- Has experienced inadequate efficacy or severe adverse event(s) to at least two ophthalmic products (as monotherapy or concomitant therapy) from two different pharmacological classes for the treatment of open-angle glaucoma or ocular hypertension (e.g., beta-blockers, alpha-agonist [brimonidine], carbonic anhydrase inhibitors, rho kinase inhibitor [netarsudil]);
- iDose TR is administered by or under the supervision of an ophthalmologist.

Approval duration: one implant per treated eye(s)

Dosing Recommendation

iDose TR is administered intracamerally through a small, clear corneal incision and is anchored into the sclera at the iridocorneal angle.

The recommended dose is one iDose TR implant per treated eye(s), two implants per patient.

References

1. iDose® TR intracameral implant [prescribing information]. San Clemente, CA: Glaukos; January 2026.
2. Goyal A. Understanding glaucoma: symptoms, causes, diagnosis, treatment. Available at: <https://www.aao.org/eye-health/diseases/what-is-glaucoma>. Published January 5, 2026. Accessed on February 19, 2026
3. Gedde SJ, Vinod K, Wright MW, et al. The American Academy of Ophthalmology. Primary Open-Angle Glaucoma Preferred Practice Pattern.® 2020 Available at: [https://www.aaojournal.org/article/S0161-6420\(20\)31024-1/fulltext](https://www.aaojournal.org/article/S0161-6420(20)31024-1/fulltext). Accessed on February 19, 2026.
4. Durysta® [prescribing information]. North Chicago, IL: AbbVie; October 2024.